Cargando…
Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients: A Prospective Observational Study
INTRODUCTION: Patients with cardiogenic shock (CS) are at a high risk of developing infectious complications; however, their early detection is difficult, mainly due to a frequently occurring noninfectious inflammatory response, which accompanies an extensive myocardial infarction (MI) or a postcard...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266423/ https://www.ncbi.nlm.nih.gov/pubmed/27749762 http://dx.doi.org/10.1097/SHK.0000000000000756 |
_version_ | 1782500468654604288 |
---|---|
author | Parenica, Jiri Jarkovsky, Jiri Malaska, Jan Mebazaa, Alexandre Gottwaldova, Jana Helanova, Katerina Litzman, Jiri Dastych, Milan Tomandl, Josef Spinar, Jindrich Dostalova, Ludmila Lokaj, Petr Tomandlova, Marie Pavkova, Monika Goldergova Sevcik, Pavel Legrand, Matthieu |
author_facet | Parenica, Jiri Jarkovsky, Jiri Malaska, Jan Mebazaa, Alexandre Gottwaldova, Jana Helanova, Katerina Litzman, Jiri Dastych, Milan Tomandl, Josef Spinar, Jindrich Dostalova, Ludmila Lokaj, Petr Tomandlova, Marie Pavkova, Monika Goldergova Sevcik, Pavel Legrand, Matthieu |
author_sort | Parenica, Jiri |
collection | PubMed |
description | INTRODUCTION: Patients with cardiogenic shock (CS) are at a high risk of developing infectious complications; however, their early detection is difficult, mainly due to a frequently occurring noninfectious inflammatory response, which accompanies an extensive myocardial infarction (MI) or a postcardiac arrest syndrome. The goal of our prospective study was to describe infectious complications in CS and the immune/inflammatory response based on a serial measurement of several blood-based inflammatory biomarkers. METHODS: Eighty patients with CS were evaluated and their infections were monitored. Inflammatory markers (C-reactive protein, procalcitonin, pentraxin 3, presepsin) were measured seven times per week. The control groups consisted of 11 patients with ST segment elevation myocardial infarction without CS and without infection, and 22 patients in septic shock. RESULTS: Infection was diagnosed in 46.3% of patients with CS; 16 patients developed an infection within 48 h. Respiratory infection was most common, occurring in 33 out of 37 patients. Infection was a significant or even the main reason of death only in 3.8% of all patients with CS, and we did not find statistically significant difference in 3-month mortality between group of patients with CS with and without infection. There was no statistically significant prolongation of the duration of mechanical ventilation associated with infection. Strong inflammatory response is often in patients with CS due to MI, but we found no significant difference in the course of the inflammatory response expressed by evaluated biomarkers in patients with CS with and without infection. We found a strong relationship between the elevated inflammatory markers (sampled at 12 h) and the 3-month mortality: the area under the curve of receiver operating characteristic ranged between 0.683 and 0.875. CONCLUSION: The prevalence of infection in patients with CS was 46.3%, and respiratory tract infections were the most common type. Infections did not prolong statistically significantly the duration of mechanical ventilation and did not increase the prevalence of hospital mortality in this high-risk CS population. CS due to acute myocardial infarction was accompanied by a strong and highly variable inflammatory response, but it did not reach the intensity of the inflammatory response observed in patients with septic shock. An extensive immune/inflammatory response in patients with CS is linked to a poor prognosis. |
format | Online Article Text |
id | pubmed-5266423 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-52664232017-02-08 Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients: A Prospective Observational Study Parenica, Jiri Jarkovsky, Jiri Malaska, Jan Mebazaa, Alexandre Gottwaldova, Jana Helanova, Katerina Litzman, Jiri Dastych, Milan Tomandl, Josef Spinar, Jindrich Dostalova, Ludmila Lokaj, Petr Tomandlova, Marie Pavkova, Monika Goldergova Sevcik, Pavel Legrand, Matthieu Shock Clinical Aspects INTRODUCTION: Patients with cardiogenic shock (CS) are at a high risk of developing infectious complications; however, their early detection is difficult, mainly due to a frequently occurring noninfectious inflammatory response, which accompanies an extensive myocardial infarction (MI) or a postcardiac arrest syndrome. The goal of our prospective study was to describe infectious complications in CS and the immune/inflammatory response based on a serial measurement of several blood-based inflammatory biomarkers. METHODS: Eighty patients with CS were evaluated and their infections were monitored. Inflammatory markers (C-reactive protein, procalcitonin, pentraxin 3, presepsin) were measured seven times per week. The control groups consisted of 11 patients with ST segment elevation myocardial infarction without CS and without infection, and 22 patients in septic shock. RESULTS: Infection was diagnosed in 46.3% of patients with CS; 16 patients developed an infection within 48 h. Respiratory infection was most common, occurring in 33 out of 37 patients. Infection was a significant or even the main reason of death only in 3.8% of all patients with CS, and we did not find statistically significant difference in 3-month mortality between group of patients with CS with and without infection. There was no statistically significant prolongation of the duration of mechanical ventilation associated with infection. Strong inflammatory response is often in patients with CS due to MI, but we found no significant difference in the course of the inflammatory response expressed by evaluated biomarkers in patients with CS with and without infection. We found a strong relationship between the elevated inflammatory markers (sampled at 12 h) and the 3-month mortality: the area under the curve of receiver operating characteristic ranged between 0.683 and 0.875. CONCLUSION: The prevalence of infection in patients with CS was 46.3%, and respiratory tract infections were the most common type. Infections did not prolong statistically significantly the duration of mechanical ventilation and did not increase the prevalence of hospital mortality in this high-risk CS population. CS due to acute myocardial infarction was accompanied by a strong and highly variable inflammatory response, but it did not reach the intensity of the inflammatory response observed in patients with septic shock. An extensive immune/inflammatory response in patients with CS is linked to a poor prognosis. Lippincott Williams & Wilkins 2017-02 2017-01-13 /pmc/articles/PMC5266423/ /pubmed/27749762 http://dx.doi.org/10.1097/SHK.0000000000000756 Text en Copyright © 2016 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Shock Society. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 |
spellingShingle | Clinical Aspects Parenica, Jiri Jarkovsky, Jiri Malaska, Jan Mebazaa, Alexandre Gottwaldova, Jana Helanova, Katerina Litzman, Jiri Dastych, Milan Tomandl, Josef Spinar, Jindrich Dostalova, Ludmila Lokaj, Petr Tomandlova, Marie Pavkova, Monika Goldergova Sevcik, Pavel Legrand, Matthieu Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients: A Prospective Observational Study |
title | Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients: A Prospective Observational Study |
title_full | Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients: A Prospective Observational Study |
title_fullStr | Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients: A Prospective Observational Study |
title_full_unstemmed | Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients: A Prospective Observational Study |
title_short | Infectious Complications and Immune/Inflammatory Response in Cardiogenic Shock Patients: A Prospective Observational Study |
title_sort | infectious complications and immune/inflammatory response in cardiogenic shock patients: a prospective observational study |
topic | Clinical Aspects |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5266423/ https://www.ncbi.nlm.nih.gov/pubmed/27749762 http://dx.doi.org/10.1097/SHK.0000000000000756 |
work_keys_str_mv | AT parenicajiri infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy AT jarkovskyjiri infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy AT malaskajan infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy AT mebazaaalexandre infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy AT gottwaldovajana infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy AT helanovakaterina infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy AT litzmanjiri infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy AT dastychmilan infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy AT tomandljosef infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy AT spinarjindrich infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy AT dostalovaludmila infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy AT lokajpetr infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy AT tomandlovamarie infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy AT pavkovamonikagoldergova infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy AT sevcikpavel infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy AT legrandmatthieu infectiouscomplicationsandimmuneinflammatoryresponseincardiogenicshockpatientsaprospectiveobservationalstudy |